Research programme: CD26 antigen antagonists - Shanghai Hengrui Pharmaceuticals

Drug Profile

Research programme: CD26 antigen antagonists - Shanghai Hengrui Pharmaceuticals

Alternative Names: Azabicyclo octane derivatives - Shanghai Hengrui; Dipeptidyl peptidase IV inhibitors - Shanghai Hengrui

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shanghai Hengrui Pharmaceutical
  • Class Cyclopentanes; Heterocyclic bicyclo compounds; Nitriles; Pyrrolidines; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in China (PO)
  • 21 Aug 2008 Pharmacokinetics and pharmacodynamics data from a Preclinical trial in Type-2 diabetes mellitus presented at the 236th American Chemical Society National Meeting (236th-ACS-2008)
  • 10 Apr 2008 Preclinical trials in Type-2 diabetes mellitus in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top